



INVESTOR PRESENTATION

August 2023



DISCLAIMER

Introduction

THIS DOCUMENT IS NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, IN WHOLE OR IN PART, DIRECTLY OR INDIRECTLY, IN OR INTO OR FROM THE UNITED STATES OF AMERICA OR TO ANY RESIDENT THEREOF, OR ANY OTHER JURISDICTION WHERE SUCH RELEASE, PUBLICATION OR DISTRIBUTION IS UNLAWFUL. THIS DOCUMENT IS NOT AN OFFER OR INVITATION TO BUY OR SELL SECURITIES.

This presentation has been prepared by CurveBeam AI Limited (ACN 140 706 618) (**CurveBeam** or the **Company**) and contains summary information about CurveBeam and the business conducted by it as at 28 July 2023. The information in this presentation is for informational purposes only, does not purport to be complete and is not a prospectus, product disclosure statement or other disclosure document for the purposes of Chapter 6D or Part 7.9 of the Corporations Act 2001 (Cth) (**Act**) or other offer document under Australian law or the law of any other jurisdiction.

The distribution of this document outside of Australia may be restricted by law and any such restrictions should be observed. This document may not be distributed or released to any person in the United States. As further detailed below, none of CurveBeam, nor its advisers (**Advisers**) nor their respective affiliates, related bodies corporate (as defined in the Act) or security holders and their respective directors, officers, employees, partners, representatives, consultants, agents or advisers (each a **Limited Party** and together, the **Limited Parties**) guarantees or make any representation or warranty to, or takes responsibility for, the accuracy, reliability or completeness of the information contained in this presentation, to the recipient of this document (you or the Recipient), and nothing contained in this document is, or may be relied upon as, a promise or representation, whether as to the past or future. To the maximum extent permitted by law, each Limited Party disclaims any liability for any loss arising from the use of information including representations or warranties or in relation to the accuracy or completeness of the information, statements, opinions or matters, express or implied, contained in, arising out of or derived from, or for omissions from, this presentation.

Not an offer or financial product advice

The information contained in this presentation is for informational purposes only and should not be considered, and does not contain or purport to contain, an offer, invitation, solicitation or recommendation with respect the purchase or sale of any securities in CurveBeam nor does it constitute legal, taxation, financial product or investment advice. The general information in this presentation has been prepared without taking into account the investment objectives, financial situation or particular needs of any particular person. Recipients of the presentation must undertake their own independent investigations, consideration and evaluation. By accepting this presentation, a Recipient agrees that if it proceeds further with its investigations, consideration or evaluation of investing in CurveBeam it will not in any way rely upon this document. Neither this presentation nor any of its contents will form the basis of any contract or commitment and it is not intended to induce or solicit any person to engage in any transaction nor is it intended to be used as the basis for making an investment decision. CurveBeam recommends that potential investors consult their professional advisors as an investment in CurveBeam is subject to investment and other known and unknown risks, some of which are beyond the control of CurveBeam

or its directors and therefore any investment is considered to be speculative in nature.

Forward looking statements

The information given in this presentation is given for illustrative purposes only and should not be relied upon as (and is not) an indication of CurveBeam's views on future performance or condition. Past performance cannot be relied upon as an indicator of future performance. This presentation contains certain forward-looking statements. The words "forecast", "estimate", "like", "anticipate", "opinion", "should", "could", "may" and other similar expressions are intended to identify future earnings, financial position and performance of CurveBeam. You are cautioned not to place undue reliance on these statements. These forward-looking statements are based on estimates, projections and assumptions made by CurveBeam about circumstances and events that have not yet taken place. Although due care and attention has been used in the preparation of these statements, such forward-looking statements are based on numerous assumptions regarding CurveBeam's present and future business strategies and the political, regulatory and economic environment in which CurveBeam will operate in the future and are subject to change without notice. Statements about market and industry trends, which are based on interpretations of current market conditions, may not be reasonable, and are not guarantees or predictions of future performance.

The actual results or performance of CurveBeam may be materially different from the results or performance expressed or implied by such forward-looking statements. No representation, warranty or assurance (express or implied) is given or made in relation to any forward-looking statement by any person (including any of the Limited Parties). In particular, no representation, warranty or assurance (express or implied) is given that the occurrence of the events expressed or implied in any forward-looking statement in this presentation will actually occur). Subject to any continuing obligations under applicable law, the Company expressly disclaims any obligation or undertaking to provide any updates or revisions to any forward-looking statements in this presentation to reflect any change in expectations in relation to any forward-looking statement or any change in events, conditions or circumstances on which any statement is based.

Financial information


All numbers in this presentation are stated in Australian dollars (**A\$**) unless stated otherwise.

EXECUTIVE SUMMARY

Company overview	<ul style="list-style-type: none"> CurveBeam AI is a developer and manufacturer of natural bilateral weight bearing CT devices Targeting improved visual assessment for doctor diagnosis, prognosis and management of orthopaedic and bone health issues Corporate HQ in Melbourne. Operational HQ in Hadfield PA, USA ~A\$85m capital raised Currently 50+ employees in Australia and the US plus 18 regional distributors
Products & Solutions	<ul style="list-style-type: none"> CurveBeam AI has developed a suite of weight bearing and non weight bearing CT devices Weight Bearing CT (WBCT) provides 3D scans of joints under weight, enabling more accurate visualisation and assessment The high resolution and 3D visualisation capabilities of the Company's devices enable the development of new AI based clinical assessment tools AI Modules - CurveBeam AI is developing a range of cloud-based AI modules to assist doctors in diagnosis and surgical planning
Significant addressable markets	<ul style="list-style-type: none"> Multibillion dollar market opportunities in the US alone <ul style="list-style-type: none"> Point of Care CT Imaging equipment – circa A\$10b Bone Health (fracture prevention) – circa A\$4.1b p.a.
Recognised customer institutions & global leader partnership (F&A)	<ul style="list-style-type: none"> CurveBeam AI achieved pro-forma A\$11.48m revenue for FY23 (representing circa 55% growth yoy) 170 device placements worldwide including well recognised medical institutions – UCLA, Duke, Mayo, HSS US co-marketing & distribution agreement with Foot & Ankle (F&A) division of Stryker Corporation (NYSE:SYK) (Market cap US\$108b) 40 placements of leading HiRise device to orthopaedic practices in the US, EU, Australia and other jurisdictions to the end of FY23
Commercialisation strategy	<ul style="list-style-type: none"> Utilising its partnership with Stryker, its distributors and its direct sales force, CurveBeam AI targets to expand its installed base of CT devices in key geographies including the key markets of the US and Germany Once FDA cleared AI modules can be uploaded to existing CT devices, AI modules targeting an annuity style SaaS revenue of US\$100k - \$125k per device at a ~90% gross margin
Regulatory approvals and favourable reimbursement status	<ul style="list-style-type: none"> CT Devices - FDA cleared, CE Marked and ARTG listed and in-market AI Modules - FDA Breakthrough designation for Ossview SFS AI module. Under FDA review for InReach HR-pQCT Favourable reimbursement for WBCT scans through existing CT CPT Codes & non-specific Payer Coverage
Clinical validation & Strong IP portfolio	<ul style="list-style-type: none"> 14 granted U.S. patents & 6 pending U.S. applications, 12 granted Australian patents & 2 pending applications, 11 other granted patents, & 19 pending applications Extensive peer reviewed publications on Weight Bearing CT Over 10 years of clinical validation in bone fragility diagnostics using bone microstructure 2,000 woman, 8-year prospective study to the clinical end point of a fragility fracture
IPO Offering	<ul style="list-style-type: none"> CurveBeam AI raised A\$25m in its ASX IPO IPO offer proceeds will be used to expand sales and marketing investment primarily in the US, to continue R&D and new product development and to fund further clinical trials.

INVESTMENT HIGHLIGHTS

Combining Weight Bearing CT (WBCT) imaging equipment with AI solutions to target faster, more efficient point of care clinical assessment aids in orthopaedics & bone health



CurveBeam AI's HiRise Weight bearing CT



First to market

Natural bilateral WBCT & Non WBCT, point of care imaging with targeted proprietary AI solutions

Advanced Regulatory

FDA cleared, TGA & CE marked CT imaging equipment. Targeting regulatory submissions for AI modules

Favourable US Reimbursement in Place

Coding, payment & coverage under existing policies

Large Market Opportunities

Large billion-dollar addressable markets

US partnership established with market leader

Co-marketing & distribution agreement with Stryker Corporation US Foot & Ankle division (NYSE:SYK)

Growing sales

A\$11.48m FY23 pro-forma revenue, circa 55% growth – CT footprint key to building SaaS annuity from AI modules with circa ~90% gross margins

KOL & Clinical Validation

Key KOL sites as users – Mayo, Duke, HSS
10 years of publications on bone fragility & WBCT

Experienced board & management


with supportive institutional investors - **Karst Peak, Tenmile, Firetrail, Acorn, SG Hiscock, Ilwella, Frazis Capital**

Building IP position

37 granted patents and 27 pending patents internationally

CURVEBEAM AI CT DEVICES & AI SOLUTIONS

CurveBeam AI has a range of CT imaging devices with visualisation applications in orthopaedics and bone health. CurveBeam AI's imaging devices have regulatory clearances and will provide the platform for the company's AI modules (post regulatory clearances)



* Does not include all CurveBeam AI products




01

COMMERCIALISATION STRATEGY

LAND & EXPAND COMMERCIALISATION STRATEGY

With over 170 first & second-generation installations worldwide, CurveBeam AI is well placed to upgrade its global install base to the HiRise for targeting high margin AI module revenue

- CurveBeam AI utilises a combination of specialist distributors and direct salesforce to drive global sales
- Fast growing sales pipeline to build on over 170 existing installations worldwide
- 40 HiRise units placed since FDA clearance in late 2020 to end FY23. Circa 75% of placements in the US market
- Targeting an installed base of HiRise systems across key global markets including the US and Germany
- Targeting commencement of SaaS revenue from AI modules by late FY25



LARGE MARKET OPPORTUNITY AND ONGOING ADOPTION BY LEADING CUSTOMERS

CurveBeam AI's target customer groups

Potential US WBCT Installation Sites¹

Potential US Addressable Market²

Select CurveBeam AI customers

Orthopaedic Surgeons & Group Practices

Surgeon group practices that have imaging capability

5,829

A\$3.6b

Imaging Chains

Orthopaedic Diagnosis, Surgical planning, fragility fracture diagnosis & management

>6,000

>A\$3.7b

Hospital based

Medium to large hospitals - can incorporate surgical planning for implants, fractures

5,460

A\$3.4b

Integrated Healthcare Networks (IHN)

Imaging departments for today, new Point of Care solutions for the future

Total

>17,352

>A\$10b

- Mayo Clinics (all 3 major locations)
- NYU Langone Health
- UCLA Orthopedic Institute for Children
- Kent State University – College of Podiatric Medicine
- Duke Orthopedics
- Midwest Orthopedics at Rush, Chicago
- Penn Medicine – Pennsylvania Hospital
- Hospices Civils De Lyon, France
- Massachusetts General Hospital, Boston
- Schön Klinik, Munich, Germany
- Hospital for Special Surgery, New York
- Ghent University Hospital, Belgium

1. Source: Frost & Sullivan

2. US HiRise indicative price US\$410,000 x \$1.50 USD/AUD potential installation sites in the US

STRONG INVESTMENT PROPOSITION FOR SURGEONS

Existing reimbursement codes create an attractive financial model for HiRise users

- The average Medicare reimbursement rate for scans of the lower extremity CPT code relevant to the HiRise™, pedCAT™ and LineUP™ was US\$138.77 per scan in 2022.
- With an initial capital cost of USD\$410,000 and assuming 10 scans per day, the payback period for a HiRise™ (excluding costs) is 1 year and 5 months
- If financed under a lease with an interest rate of 9%, the breakeven number of scans required to pay the machine off over a 5-year term is 2.83 scans per day (excluding costs)



Atlantic Orthopedic Specialists,
Virginia Beach, VA

Actual CurveBeam Customer - PedCat

Device up front cost: \$179,000

Volume: 35 scans per month

Breakeven: 17 scans/month

Reimbursement range: \$99.74 to \$294.31

Average reimbursement: \$242.11

Gross revenue / month: \$7014.08

Device payback period of 2.5 years

1. US Payment and coverage varies extensively city to city, state to state and this example represents a specific model for a specific region of the US market

STRYKER FOOT & ANKLE CO-MARKETING & DISTRIBUTION US PARTNERSHIP

Stryker is a market leader in orthopaedics with US\$18b in sales in FY22.



STRYKER CORPORATION (NYSE:SYK) BACKGROUND

- Leading multinational medical technology company with innovative products and services in Medical and Surgical, Neurotechnology, Orthopedics and Spine
- Market leader (Mkt Cap: A\$170b) in orthopaedics with US\$18b in sales in FY22
- Orthopedics & Spine contributes circa 55% of Stryker's US\$18b sales
- Stryker have several large product categories in Orthopaedics, including Foot and Ankle and Joint Replacement dedicated to helping surgeons treat patients more efficiently while enhancing patient care
- In 2022 Stryker held the highest market share for several key foot and ankle procedures, including primary ankle replacement, total ankle fusion, midfoot fixation

STRYKER CO-MARKETING & DISTRIBUTION PARTNERSHIP

US Foot & Ankle agreement. Stryker targets HiRise placements to drive sales of their orthopaedic product suite



CURVEBEAM AI & STRYKER PARTNERSHIP

- US Co-marketing & Distribution partnership - Stryker Foot & Ankle Division
- Launched at American Orthopedic Foot and Ankle Society (AOFAS) conference September 2022
- The HiRise will be Stryker's first imaging solution sold through its Foot & Ankle division
- HiRise units will be preloaded with Stryker Prophecy surgical planning protocols, to further solidify Stryker incentives for placing devices
- Stryker's sales managers trained on CurveBeam AI equipment in January 2023
- In May 2023, Stryker Foot & Ankle unit officially launched its HiRise promotion, distribution and financing program, and qualified CurveBeam as an approved supplier. This includes access to Stryker's various attractive "Flex Financing" options for customers

REGULATORY & REIMBURSEMENT OVERVIEW

Over 10 years of regulatory and clinical development and clearances underpin CurveBeam AI's industry leading competitive position

REGULATORY CLEARANCES

- FDA cleared, CE Marked and ARTG listed for CT devices and visualisation software to allow the sale of CurveBeam AI's weight bearing CT devices in several markets, including the U.S., Europe and Australia
- FDA Breakthrough designation for Ossview SFS, and under review with FDA on the InReach HR-pQCT for the wrist. Clearance expected in FY24
- FDA Filing targeted for Bone Mineral Density (FY24) and for OssView microstructure ankle (FY24) on HiRise
- Cubevue AutoMetrics FDA filing targeted for FY24 – value-add tool for users

FAVOURABLE REIMBURSEMENT IN US & GERMANY

- Favourable reimbursement¹ for CT scans (US/Germany) through existing CT CPT Codes & Payer Coverage
- Favourable reimbursement for BMD CT off HiRise for the US only – once HiRise BMD CT is FDA cleared
- Company intends to target an additional payment for the OssView score, once FDA cleared
 - The Company intends to work with a large, capitated network to demonstrate clinical efficacy & care-cost reduction in the network's population health management program to agree a capitated system payment

CLINICAL DEVELOPMENT

- Extensive peer reviewed publications on Weight Bearing CT
- Over 10 years of clinical validation in bone fragility diagnostics using bone microstructure analysis
- 2,000-woman, 8-year prospective study, to clinical end point of fragility fracture

1. 'Favourable' reimbursement is defined as where there are enough reimbursed scans to pay for the device placement through a typical 4 to 5 year lease



03

ORTHOPAEDIC DIAGNOSIS AND PLANNING


WEIGHT BEARING CONE BEAM CT FOR TOTAL ALIGNMENT

- ✓ **Quicker and easier** to scan than traditional CT and MRI, with faster image acquisition time
- ✓ **High resolution** and **3D visualisation** enables **development of new AI based assessment tools**
- ✓ **Radiation dose lower** than traditional CT – up to 66% less than traditional CT
- ✓ **Smaller and lower-cost hardware** requiring limited radiation shielding infrastructure



Hip to Foot in standing 3D

HiRise is the first product capable of WBCT of hip to foot in standing 3D



Weight bearing imaging key to accurate diagnosis

WBCT provides unique alignment data required to accurately assess bone positioning under standing load



Serves more applications

The HiRise serves various orthopaedic sub-specialties in total knee, hip and ankle replacement planning in addition to implant manufacturers and 3D printed solution providers

HIRISE: WEIGHT BEARING CT


The HiRise currently provides many advantages in improving CT visualisation of clinical issues to improve diagnosis and surgical planning



Comfortable patient experience for weight bearing hip, knee and foot scans as well as upper extremity and supine positions



Included visualisation software, CubeVue, displays dynamic 3D renderings, multiplanar slices and digitally reconstructed radiographs in about 3 minutes per scan region.



Approximately 1-3 minutes per scan per joint, with less than 30 seconds of X-ray exposure

APPLICATIONS CURRENTLY SERVED

- Suspected hip, knee and ankle fractures
- Suspected osteoarthritis
- Bunions
- AAFD reconstructions
- Joint Replacements
- Charcot foot reconstruction
- High Ankle sprain (Syndesmosis)
- Lisfranc Injuries
- ORIF (calcaneus, pilon, ankle)
- Triple arthrodesis

ADVANTAGES

- In-clinic scanning
- Faster diagnosis and follow up
- Reduced risk of revision surgery
- Improved treatment and patient satisfaction
- Improved outcomes and reduced adverse outcomes

USER TESTIMONIALS

“ The image quality is unparalleled and the efficiencies are invaluable. Daily, we are diagnosing pathology that otherwise would have been missed or delayed. Treatment is expedited and outcomes are better. Patients love it.

- Dr. Kyle Kinmon, DPM; Certified Foot & Ankle, Boca Raton, FL



“ We all know that the 3D morphology is overlapping and it's sometimes very difficult to tell on plain films. So, this really does heighten our ability to make a diagnosis and examine patients.

- Dr. Josef Zoldos, MD, Arizona Center for Hand Surgery

“ InReach has been an excellent asset allowing in-office imaging and rapid CT evaluation of the hands with complex diagnostic dilemmas.

- Dr. Lloyd Champagne, MD, Arizona Center for Hand Surgery



“ Weight bearing CT scan has been the most important addition to my practice since starting. It greatly enhances the level of care and sophistication of preoperative planning.

- Dr. Blake Moore, MD, Atlantic orthopaedic Specialists





“ The weight bearing CT changed my daily practice. In former times we did standard X-Rays with weight bearing first and then if we were interested in 3D imaging, we sent the patient to CT. This could take days or even weeks. Now, I have everything together in one minute.

- Dr. Martinus Richter, MD, Hospital Rummelsberg




USER TESTIMONIALS



WBCT IN THE NEWS:

President-Elect Joe Biden gets Weight Bearing CT Scan to Monitor Lisfranc Healing Progression



Images are a generic example of midfoot pathology.


- In 2020, President Joe Biden's physician recommended he get a weight bearing CT scan to monitor the healing progression of a sustained hairline fracture
- President Biden was scanned by a pedCAT weight bearing CT system
- "It is important to observe the structures within the mid foot under the actual pressure of standing. This is the best way to assure ankle and foot stability" Dr. Kevin O'Connor of GW Medical Associates (advisors to the then President-elect).
- Dr. O'Connor later assumed the role of White House Doctor, once Mr. Biden was sworn-in as president.

AI MODULES WILL TARGET HIGH MARGIN REVENUE ON HIRISE INSTALL BASE

CubeVue AutoMetrics aims to reduce 16 hours of CT dataset preparation prior to pre-surgical planning to a scan available in 15 minutes

"To minimize future predicted costs, morbidity, & mortality from increasing numbers of fragility fractures in our rapidly aging population, the AAOS recommends that bone fragility should become a national public health priority"


- American Association of Orthopedic Surgeons (AAOS)



THE PROBLEM

Aids in bone segmentation for accurately identifying key anatomical points

- Orthopaedic pre-treatment planning involves understanding of the structure and alignment of the foot – 26 bones & 33 joints
- To segment the bones in the foot and accurately assess bone geometry & alignment requires ~6 hours of manual effort. Not feasible in practice
- Typically, surgeons will make crude manual measurements on 2D radiographs
- No reimbursement in place at this point



THE SOLUTION

CurveBeam AI DLAI segmentation-as-a-service model

- Working 3D model with measurements in minutes for surgeons
- WBCT images drive improvements in accuracy & consistency
- CBAI has several key patents awarded in DLAI & non-AI for bone segmentation
- Targeting this IP for a platform solution for other CT modalities, in addition to WBCT (B2B)
- FDA filing expected in FY2024



04

BONE HEALTH DIAGNOSTICS

MUSCULOSKELETAL ISSUES ARE SIGNIFICANT FOR HEALTH CARE SYSTEMS

Enhanced imaging data can aid in the clinical assessment and treatment of Osteoarthritis and Osteoporosis


OSTEOPOROSIS

- Osteoporosis is where bone mass, structure and strength decreases, increasing the risk of fragility fractures
- Osteoporosis affects **over 14 million individuals over the age of 50 in the US**, however most fragility fractures occur in non-osteoporotic patients
- Approximately **1 in 3 women and 1 in 5 men over the age of 50** will be affected by a fragility fracture in their lifetime

OSTEOARTHRITIS

- Osteoarthritis is caused by joint damage when the protective cartilage that cushions the ends of the bones wears down over time
- Osteoarthritis affects **1 in 7 US adults**

Estimated cost to US Health Care System (US\$b)



Source: Frost & Sullivan

BONE HEALTH: CURRENT BONE HEALTH DIAGNOSTIC (DEXA) MISSES THE MAJORITY OF FRAGILITY FRACTURES


Bone fragility is caused by loss of bone microstructure, BMD measures only bone density & not microstructure

BONE MINERAL DENSITY (BMD): CURRENT STANDARD OF CARE

Commonly administered, limited performance



DEXA: Dual-energy X-ray is a means of measuring bone mineral density (BMD).



It basically looks at a silhouette of bone for determining density, as compared to a normal healthy population.

Small changes in bone density can mask major microstructural changes in the cortical and trabecular bones

BONE MICROSTRUCTURE




3 electron micrographs – a normal bone density control & female patients of age

- Note - loss of bone microarchitecture is associated with aging
- While loss of bone density contributes to fragility, the major cause of fragility is loss of microstructure
- Bone loss may reduce BMD modestly & it can mask major microstructural changes

BMD AND OSSVIEW OVERVIEW

CurveBeam AI's proprietary SaaS solutions leverage CT scans generated from its HiRise device

HiRise a change agent




HiRise



BONE MINERAL DENSITY

- AI driven BMD report utilising CurveBeam AI's high resolution CT scans for BMD (hip) & bone microstructure (ankle) assessment. Possible only on the HiRise
- Under development - target FDA 510(k) filing in FY24
- On FDA clearance, the company expects to be able to provide BMD reports in conjunction with imaging for total joint replacements, with a goal to prevent revision surgery
- **Favourable reimbursement in place in the US market**

Healthy Bone Patient's Bone




OssView (SFS)

- AI generated report for aiding physicians in the assessment of fracture risk with non osteoporotic BMD
- OssView awarded **FDA Breakthrough Device Designation**. Ossview (wrist) with InReach HR-pQCT presently under review by FDA (targeting clearance in FY24)
- Also to be enabled by HiRise (feature under development)
- Company is targeting payment for OssView through 2 programs, 1) under a capitated system clinical validation trial & 2) a fee for service (FFS) payer coverage. The FFS program will target AMA to assign an existing CPT code to Ossview. Coverage and payment to be targeted through clinical trials demonstrating strong health economics of OssView

THE CURVEBEAM AI SOLUTION: MICRO-CT + AI IMAGE ANALYSIS PROVIDING BONE MICROSTRUCTURE ASSESSMENT FOR FRACTURE RISK

CurveBeam AI's specialised imaging and the OssView SFS modules are targeting to provide a step change in aiding a clinician in fracture risk assessment, with & without BMD





05

EXPERIENCED BOARD AND MANAGEMENT

EXPERIENCED BOARD



ROBERT LILLEY

Chairman, BA (Yale)

35 years' experience in medical device and diagnostics industry. Previously senior vice president of global sales and marketing, Digene Corporation (Nasdaq:DIGE), a molecular diagnostics company, which was subsequently acquired by Qiagen N.V. (NYSE:QGEN).

Currently Chair of Immunexpress Pty Ltd, an Australian molecular diagnostics company.



GREGORY BROWN

Managing Director / CEO, B.app.Sc, MBA

35 years healthcare experience

Ex Baxter Diagnostics (Australia & UK), Roche Molecular (Switzerland/New York), Digene Corp (Washington DC/Germany)

2006-2012 ImpediMed CEO (IPD:ASX),

2014 – 2022 StraxCorp (Chairman & CEO);

Board experience: Trinity Biotech (NASDAQ), Immunexpress (IXP), IPD(ASX), UniQuest (UQ)



ARUN SINGH

Executive Director, COO, CTO-CT, US president

BSc & Masters Degree in Electrical Engineering
Founder, President and CEO of CurveBeam LLC

Led the development of the first commercially viable Cone Beam CT imaging system for dental and maxillofacial imaging, with 9,000+ systems deployed today globally.

Awarded Lifetime Achievement Award by the AADMRT in 2016 for his visionary contributions to the advancement of cone beam CT



HASHAN DE SILVA

Non-Executive Director, BSc (Medicine), MCom, CFA charterholder

Founder and Managing Partner of KP Rx, a specialist healthcare fund manager.

Previously head of healthcare research at Karst Peak Capital, equity research analyst in healthcare at CLSA Limited and Senior Research Associate Analyst at Macquarie Group.

Director Pharmaxis Limited (ASX:PXS)



KATE ROBB

Non-Executive Director BBus (Accounting), CA, GAICD

25 years' finance, governance, risk management and compliance experience.

Previous senior audit and risk roles at United Energy Limited (ASX:UEL), AGL Energy, ANZ

Non-Executive Director Solvar Ltd (ASX:SVR), chair SVR audit and risk committee and a member of SVR nominations and remuneration committee.

SENIOR MANAGEMENT



URA P AUCKLAND

CFO, Company Secretary

B.Bus, G.Dip Company Secretarial Practice, Columbia University Snr Exec Program 2002. Graduate of CPA program

Nearly 20 years' experience senior finance, operations and administrative roles in the technology and healthcare sectors

Previously CFO and Company Secretary of ImpediMed Limited (ASX:IPD) and held various roles at PanBio Limited (ASX:PBO) including CFO, Company Secretary and Vice-President – Point of Care



YU PENG

CTO-AI, BSc & PhD

Over 15 years' experience in computer vision and machine learning and oversees technical strategy and development at CurveBeam, including medical image analysis, machine learning and cloud computing

PhD in Computer Vision and Machine Learning from the University of Newcastle, Australia. Visiting Professor position (honorary) in Artificial Intelligence (AI) at the University of Technology, Sydney, Australia from 2019 to 2022.



S. TURNER DEAN

Chief Sales Officer

45 years of experience in healthcare and software. VP Sales and Director of Business Development for CrossTec Corp., and Executive VP of AZZLY, Inc. Co-founded and sold CrossTec Security (aka Activeworx, Inc.) to Tripwire, Inc. during his tenure at CrossTec Corp. BS in Economics from the University of Wisconsin-Whitewater.



VINTI SINGH

Vice President of Marketing, BA (Journalism), MBA

Over 14 years' communications and marketing experience. Ms Singh joined CurveBeam LLC in 2012 and has served as Vice President of Marketing following the merger of CurveBeam AI and CurveBeam LLC in 2022. Prior to this, Ms Singh was a reporter at the Hearst Connecticut Media Group. Ms Singh has a Bachelor of Journalism and a Masters of Business Administration








06

SUMMARY

CURVEBEAM TECHNOLOGY PLATFORM OVERVIEW

CurveBeam AI has regulatory clearances for WBCT devices in-market with a deep pipeline of complimentary high margin AI modules to be launched in FY25 and beyond

	SOLUTION	PRODUCTS	REGULATORY/COMMERCIAL STATUS	US MARKET OPPORTUNITY	GROSS MARGIN	REVENUE OPPORTUNITY
ORTHOPAEDICS	Weight Bearing CT for Orthopaedic visual diagnostic support and treatment planning	HiRise, PedCAT		In market		
	Next generation AI bone segmentation and 3D modelling	AutoMetrics	 FDA filing targeted for FY24 User subscription based value-add tool	~A\$10b ¹ (capital sales)	~50%	US\$410,000 per HiRise unit
BONE HEALTH	High resolution CT for assessing fracture risk with bone microstructure analysis of the wrist (OssView)	InReach HR-pQCT	 • CT device FDA cleared • Filed OssView with FDA for the wrist • FDA Breakthrough Device Designation • FDA clearance targeted for FY24	~A\$1.4b per annum ² (OssView scan revenue)	Targeting 90%+	~US\$100,000 - 125,000 future p.a SaaS target per HiRise ³ (for BMD scans only)
	AI processed Structural Fragility Score of the ankle (OssView)	AI Generated OssView Report on the HiRise ankle scan – opportunistic scan only	 FDA filing targeted for FY24			
	AI driven Bone Mineral Density assessment for hip to knee scans	AI Generated CT BMD Report on the HiRise at the hip – opportunistic scan only	 FDA filing targeted for FY24	A\$2.7b+ per annum ⁴ (BMD scan revenue)		

1. U.S. indicative install price (direct to clinician and partner sales) of HiRise™ x ~17,352 potential installation sites in the US (5,892 orthopaedic practices, 6,000+ Standalone imaging centres, 5,460 non-psychiatric hospitals)
2. 30.6m women over 65 recommended for screening based on US Preventive Services Taskforce screening recommendations x A\$90, screened every 2 years (Medicare provides BMD reimbursement every 2 years))
3. Assumes 4 to 5 BMD CT scans per day, 6 days a week, 50 weeks a year at a target scan price of US\$85 per Scan (\$85 x 100 to 125 scans per month)
4. US\$100,000 (per target SaaS revenue in note 3) x \$1.50 (being US\$1.00 = A\$1.50) x ~17,352 potential installation sites in the U.S.

INVESTMENT SUMMARY

CurveBeam AI produces and sells market leading weight bearing CT scanners. The Company has established key recognised clinical customers and a leading vendor partner. Funds raised in the IPO will be used to accelerate sales growth and invest in new product development to maintain CurveBeam AI's competitive advantage.

Regulatory Clearances	First to market, FDA cleared, TGA and CE Marked Point of Care Weight Bearing and high resolution Cone Beam CT imaging equipment
Significant addressable market	Large A\$10b plus A\$4.1b per annum addressable markets
Commercial stage	Commercial stage company with pro-forma A\$11.48m revenue for FY2023
Favourable Reimbursement	Favourable reimbursement for CT scans (US/Germany) and BMD HiRise targeted annuity (US only)
Tier 1 Partnership	Distribution partnership with the foot and ankle division of Stryker (NYSE:SYK) to aid in driving growth
Established global footprint	170+ Device placements worldwide including top tier institutions – e.g. Mayo, Duke, HSS 40 HiRise placements since FDA clearance in late 2020 to end FY23
High margin AI solutions	Installed CT devices to underpin incremental high margin AI module revenues commencing late FY25
A\$25m IPO	IPO proceeds to fund US sales growth and key new product development



CurveBeam AI

THANK YOU

